NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen, Inc (NASDAQ:AXGN) issued its quarterly earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.04. The medical equipment provider earned $28.56 million during the quarter, compared to analysts' expectations of $28.10 million. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. View AxoGen's Earnings History.

AxoGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for AxoGen.

AxoGen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.6 million, compared to the consensus revenue estimate of $107.76 million.

5 analysts have issued twelve-month target prices for AxoGen's shares. Their forecasts range from $21.00 to $30.00. On average, they expect AxoGen's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 91.9% from the stock's current price. View Analyst Price Targets for AxoGen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

News coverage about AXGN stock has been trending positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AxoGen earned a news sentiment score of 2.2 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for AxoGen.

AxoGen saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 1,950,000 shares, an increase of 10.2% from the November 28th total of 1,770,000 shares. Based on an average daily trading volume, of 364,600 shares, the days-to-cover ratio is currently 5.3 days. Approximately 5.5% of the shares of the stock are sold short. View AxoGen's Current Options Chain.

Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), Cutera (CUTR), TransMedics Group (TMDX), Zynex (ZYXI), Stereotaxis (STXS), BioLife Solutions (BLFS), Semler Scientific (SMLR), Viewray (VRAY), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Xilinx (XLNX), Advanced Micro Devices (AMD), Micron Technology (MU), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Amarin (AMRN) and NVIDIA (NVDA).

AxoGen's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.43%) and Pennsylvania Trust Co (0.51%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Pennsylvania Trust Co. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $13.03.

AxoGen has a market capitalization of $514.29 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.

The official website for AxoGen is http://www.axogeninc.com/.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]